Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NitroMed/NAACP alliance

Executive Summary

NitroMed provides a $1.5 mil. grant to the National Association for the Advancement of Colored People to develop "health advocacy initiatives towards equal access to quality healthcare," the firm announces Dec. 14. Among other initiatives, the grant will support the development of a "consensus paper on the state of African American healthcare and the impact of Medicare" and an Advocacy Action Plan for the NAACP National Health Leadership Committee. NitroMed markets BiDil (isosorbide dinitrate/hydralazine), which was approved in June for treatment of heart failure in self-identified black patients, and is the first therapy indicated for a specific ethnic population (1"The Pink Sheet" June 27, 2005, p. 5)...

You may also be interested in...



BiDil Approval In Blacks Is Step Toward Personalized Medicine, FDA Says

The approval of NitroMed's BiDil for treatment of heart failure in self-identified blacks is a step in the direction of drugs based on patient characteristics

Signs Of Hope But Obstacles Remain For Swiss Device MRA With EU

Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.

Amneal Ready To Go Head-To-Head With Mylan’s Xulane In US

Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel